Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Inflazyme Pharmaceuticals (T.IZP) -- Ignore unavailable to you. Want to Upgrade?

To: Sean Janzen who wrote (966)	6/4/1998 9:29:00 PM
From: Harold Lehman	Respond to of 1501

We have so little information about what is really going on that it's hard to venture a guess as to whether they are near a joint venture deal (hopefully still left on the table by a big pharma or three after 2 1/2 years of Salari's skillful negociations), or what Cortecs is up to, or whether this financing is simply a security blanket of sorts. I even wonder whether this private placement would be going to people who may have shorted millions of shares at much higher prices from offshore accounts, which Salari himself had repeatedly suggested existed, who could then safely cover their positions with no risk whatsoever. See, this is what happens when management has no respect for their noninstitutional shareholders, they begin to think up all sorts of scenarios. Meanwhile Rothchilds' Asset Management has a seat on the board of directors so they (and Goldman Sachs) probably know everything that's going on in a very timely fashion. By the way, if you want to make your views and suggestions known to McBeast, I mean McBeath, the new CEO, his e-mail address is info@inflazyme.com. At least that's what I was told. I haven't e-mailed my views about their shareholder communications or questions about the status of things we have all discussed and I encourage everyone to do so so they understand that there are real concerned people among their shareholding public. One more thing. The phone number of Dr. Michael Flynn, who is listed as President of Cortecs, is 44-181-232-1900. It's in the UK. I don't want to call their project manager, Phil Goodwin, who I spoke with ~3-4 months ago as he seemed testy at that time. I'm going to try to get hold of Flynn, and if anyone here feels like, PLEASE DO. If I talk with him and get anything intelligible, I'll post it.

To: Sean Janzen who wrote (966)	6/5/1998 2:37:00 PM
From: Harold Lehman	Read Replies (1) \| Respond to of 1501

You can hold the calls to Dr. Michael Flynn, President of Cortecs. He called me back this morning regarding the tb antigen test. He first checked with their Diagnostics Director, who told him that there's been no adverse event or adverse change of any kind since the last public statement was made. He didn't know when that was or if there's been any public statement since the collaboration was announced as he has 60-70 projects going on. They've done a lot of work, and as far as they're concerned everything is fine with the collaboration. Everything is progressing well and they're not expecting to hear anything negative. If there is anything negative it would merit a public statement, and there's nothing like that that they're aware of at all.